Silo Pharma, Inc.

SILO

US82711P3001

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 16/07/2026 HKT			5-day change	1st Jan Change
4.875 ^USD	-4.97%		-28.10%	-4.41%

07-11	Top Midday Decliners	MT
07-10	Silo Pharma Launches Private Placement to Raise Up to $11.7 Million	MT

Top Midday Decliners

Published on 07/11/2026 at 02:07 am HKT

MT Newswires

Add MarketScreener to your sources

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Add MarketScreener to your sources

Latest news about Silo Pharma, Inc.

07-11	Top Midday Decliners	MT
07-10	Silo Pharma Launches Private Placement to Raise Up to $11.7 Million	MT
07-09	Silo Pharma, Inc. announced that it has received $4.000015 million in funding	CI
06-30	Silo Pharma Advances SPC-15 PTSD Therapeutic With Drug-Device Robustness Study Ahead Of Planned FDA Type C Meeting Request	CI
06-23	Silo Pharma, Inc. Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-In-Human Clinical Trial	CI
06-23	Silo Pharma Says SPC-15 PTSD Nasal Spray Remains Stable for 9 Months	MT
06-18	Silo Pharma Says it Regained Compliance With Nasdaq's Minimum Bid Price Requirement	MT
06-04	Silo Pharma Shares Drop Following Implementation of 1-for-15 Reverse Stock Split	MT
05-14	Tranche Update on Silo Pharma, Inc.'s Equity Buyback Plan announced on February 23, 2026.	CI
05-14	Silo Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury	CI
04-30	Silo Pharma's PTSD program advances as FDA fast-tracks psychedelic therapies for PTSD	RE
04-29	Silo Pharma, Inc. Announces Its PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD	CI
04-22	Silo Pharma, Inc. acquired Qwikagents.com, Qikagents.ai, and Qwikagents.co from Many Ads Inc. for $0.7 million.	CI
04-20	Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics	CI

Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Companyâ€™s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Companyâ€™s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimerâ€™s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimerâ€™s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.

Employees

Sector

Biotechnology & Medical Research

More about the company